SIETES :: 93213 citas

Resultados de la búsqueda por FLUFENACINA REFINAR BÚSQUEDA

1.

Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom 2020;7:abril. [Ref.ID 103647]

2.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

3.

Park H-Y, Park J-W, Sohn HS, Kwon JW. Association of parkinsonism or Parkinson disease with polypharmacy in the year preceding diagnosis: a nested case–control study in South Korea . Drug Saf 2017;40:1109-18. [Ref.ID 102104]

4.

Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]

5.

Anónimo. Two long-acting injectable antipsychotics for schizophrenia. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:152-3. [Ref.ID 99815]

6.

Leucht S, Tardy M, Komosa K, Heres S, Kissling W, Salanti G, Davis JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012;379:2063-71. [Ref.ID 93128]

7.

Anónimo. Resultados clínicos de medicamentos de marca frente a genéricos: una revisión actualizada a 28/02/11. Boletín Terapéutico Extremeño 2011;2:1-8. [Ref.ID 90001]

8.

Liperoti R, Gambassi G. Antipsychotics and the risk of venous thromboembolism. BMJ 2010;341:613-4. [Ref.ID 89403]

9.

Anónimo. Patients âgés déments et neuroleptiques: excès de mortalité. Prescrire 2010;30:427-9. [Ref.ID 88568]

10.

Carvajal A, García del Pozo J, de Abajo FJ. Utilización de antipsicóticos en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:. [Ref.ID 86458]

11.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41. [Ref.ID 84954]

12.

Tognoni G. A proposito di farmaci stabilizzanti l'"umore". Informazioni sui Farmaci 2008;32:26-8. [Ref.ID 83206]

13.

Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-89. [Ref.ID 78467]

14.

Hopkins J. Newer antipsychotic drugs are no better than older ones, study finds. BMJ 2006;333:771. [Ref.ID 78308]

15.

Isbister GK, Balit CR, Kilham HA. Antipsychotic poisoning in young children: a systematic review. Drug Saf 2005;28:1029-44. [Ref.ID 75376]

16.

Trifirò G, Espina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol 2005;61:47-53. [Ref.ID 73468]

17.

Anónimo. Antipsicóticos: ¿típicos o atípicos?. PAM 2004;28:663-700. [Ref.ID 71663]

18.

Anónimo. Choice of antipsychotic. Med Lett Drugs Ther 2003;45:102-4. [Ref.ID 68639]

19.

Freedman R. Schizophrenia. N Engl J Med 2003;349:1738-49. [Ref.ID 67976]

20.

Altamura AC, Sasseslla F, Santini A, Montresor C, Fumagalli S, Mundo E. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003;63:493-512. [Ref.ID 65850]